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Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative 
disorder characterized by the presence of a reciprocal 
translocation between chromosomes 9 and 22 (Philadelphia 
chromosome), which leads to the appearance of a new 
hybrid gene (BCR-ABL) with tyrosine kinase activity. Current 
initial therapy is the administration of the tyrosine kinase 
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A B S T R A C T
 
Long-term survivors of hematopoietic stem cell transplantation are recognized as a risk 
group for malignization. Malignant oral neoplasms are increasingly being reported in the 
literature as a consequence of lesions of chronic graft-versus-host disease, and prolonged 
multidrug treatment to control its manifestations. This report describes a 43-year-old 
patient who, after allogeneic bone marrow transplantation, developed an oral squamous cell 
carcinoma secondary to the use of azathioprine, cyclosporine, prednisone, and tacrolimus, 
associated with multiorgan chronic graft-versus-host disease involving the oral mucosa, 
skin, eyes, and liver. This report aims to discuss the possible role of immunosuppressant 
therapy for chronic graft-versus-host disease on the development of oral squamous cell 
carcinoma, and the relevance of a close oral follow-up of patients to detect dysplastic or 
malignant alterations at an early stage.
© 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by 
Elsevier Editora Ltda. All rights reserved.
inhibitor, imatinib mesylate, but in some cases, particularly 
for refractory or advanced phase disease, hematopoietic 
stem cell transplantation (HSCT) can be indicated as a 
curative treatment. However, there is concern about late 
complications of this procedure, such as chronic graft-versus-
host disease (cGVHD) and the development of malignancies 
secondary to radiotherapy, chemotherapy, and prolonged 
immunosuppressive treatment.1,2
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One of the most common late complications after HSCT is 
graft-versus-host disease (GVHD). Studies demonstrate that 
patients who develop cGVHD have higher risk of developing 
solid tumors such as oral squamous cell carcinoma (SCC), 
mainly because of the immunosuppressive treatment, 
which generally includes cyclosporine, tacrolimus, and 
corticosteroids.2,3 
The current report describes a patient with multiorgan 
cGVHD, who developed oral SCC after prolonged and combined 
immunosuppressant drug therapy.
Case report
In 2008, a 43-year-old Caucasian male patient was referred 
for an oral medical consultation from a bone marrow 
transplantation unit, with the chief complaint of widespread 
oral pain, mainly of the palate, and difficulty to open his mouth. 
In 1999, the patient had been diagnosed with CML and started 
treatment with hydroxyurea to control the leukocyte count. 
Three years later he started taking imatinib mesylate, which 
was maintained for 14 months. As there was no response to 
high doses of imatinib or its association with cytarabine, the 
patient was submitted to a HSCT in 2003. The cell donor was 
his sister and they were fully matched. The patient progressed 
with acute GVHD (aGVHD), followed by extensive multiorgan 
cGVHD. In 2004, the CML relapsed, despite severe cGVHD. 
At that time, there was no other available option and the 
patient returned to imatinib therapy (400 mg/day), which was 
maintained until 2009, with an unexpected complete molecular 
response.
An extra oral examination revealed diffuse hypochromic 
and hyperchromic skin lesions (Figure 1), and palpable 
submandibular and cervical lymph nodes. The oral examination 
revealed a very poor hygiene status, scleroderma with a severe 
limitation of mouth opening, severe mucosal atrophy and 
ulcerations, absence of tongue papillae, a pseudomembrane 
on the anterior third part of the left buccal mucosa, and an 
indurated retrocomissural ulcerated nodule of approximately 
1 cm in diameter (Figure 2). The panoramic radiographic image 
showed residual root fragments and loose teeth (Figure 3). 
The patient was taking imatinib mesylate (400 mg/day), 
prednisone (20 mg) on alternate days, trimethoprim and 
sulfamethoxazole (TMP/SMX) (80/400 mg/day), tacrolimus (4 
mg/day), azathioprine (100 mg/day), and morphine (240 mg/day). 
Information on drugs, dosage and time is summarized in Table 1.
  
Year 
 
Drug
 
Dosage
Prescription 
(days) 
2003-2005 Cyclosporinea 200-800 mg 458
Prednisone > 5 mg/kg/day 708
2005 Mycophenolate mofetil 1 g 30
2006 Cyclosporine 300 mg 270
Prednisone > 5 mg/kg/day 240
Azathioprine 100 mg 285
2007 Cyclosporine 300 mg 45
Prednisone > 5 mg/kg/day 345
Azathioprine 100 mg 365
Tacrolimus 2-4 g 330
2008-2009 Prednisone > 5 mg/kg/day 395
Azathioprine 100 g 395
Tacrolimus 2-4 g 395
a Dosage used to keep serum level between 200-400 mg/kg. 
Table 1 - Immunosuppressant treatment for acute and 
chronic graft-versus-host disease.
Figure 1 – Diffuse hypochromic and hyperchromic skin lesions 
characteristic of chronic cutaneous graft-versus-host disease.
Figure 2 – Indurate and asymptomatic retrocomissural lesion. 
Poor oral hygiene was evident with multiple acute carious lesions, 
the accumulation of gross biofilm, gingivitis and restricted mouth 
opening.
Figure 3 – Panoramic radiograph showing the poor dental status.
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The patient was immediately prescribed non-alcohol 
chlorhexidine mouthwash to control oral biofilm, and an 
incisional biopsy was performed on the retrocomissural lesion 
under local anesthesia. The microscopic analysis revealed a 
well differentiated SCC, and the patient was promptly referred 
to a head and neck surgery referral center.
Discussion
GVHD is a common and important complication after HSCT; 
its prevalence is seen in between 25% and 80% in long-term 
survivors. The 5-year survival rate after HSCT is reported 
as being approximately 40% of patients with multisystem 
cGVHD.2-5 Cumulative evidence suggests that GVHD is an 
important risk factor for carcinogenesis, and this association 
has also been described for oral tissues. 
In 1997, Curtis et al.,6 in a multi-institution database study 
of 19,229 patients, showed that cGVHD was associated to 
higher risk of SCC in the oral cavity after HSCT. All 16 cases 
of oral SCC registered were associated to GVHD, and 11 had 
received immunosuppressive drugs for two or more years. 
In that study, the most frequent site of SCC was the tongue, 
followed by the salivary glands, lips, and gingivae.
In a study with 2,129 patients who underwent HSCT, Bathia 
et al.7 found that the risk of solid cancers after transplant 
varies according to the primary diagnosis. Among hematologic 
malignancies, patients with a diagnosis of acute and chronic 
myeloid leukemia tended to have higher incidence of solid 
tumors than the general population, the risk being significantly 
higher for liver, oral cavity, and cervical cancers.
Other authors also stated that this high risk for oral SCC is 
a result of long-term immunologic injury to the oral mucosa 
by T-cells, and of immunodeficiency after prolonged drug use 
to control cGVHD. There is some speculation that oral tissue 
infections by viruses, particularly HPV, may also lead to the 
proliferation of cancer cells.2,4,8,9
It is well accepted that tissue damage results from the 
reaction of donor T cells against host histocompatibility 
antigens (HLA); this is aggravated by other known risk factors 
for cGVHD, such as gender mismatch (female donor to a male 
recipient), severity of previous aGVHD, the donor age, and older 
recipient.2,9
In the case described in this paper, the donor was female, 
and the host and donor were 35 and 38 years old, respectively 
at the time of HSCT. Moreover, the patient had an aggressive 
aGVHD 35 days after the HSCT, followed by multisystemic 
cGVHD, refractory to treatment.
Clinically, oral cGVHD resembles autoimmune disorders 
like lichen planus, scleroderma, and Sjögren’s syndrome, and 
manifests in oral tissues as inflammation and erythema, 
hyperkeratotic lesions, atrophy, fibrosis with restricted mouth 
opening, depapillation of the tongue, hyposalivation, and pain.5 
Although it is well recognized that patients have a higher 
risk of oral complications after HSCT, such as tooth decay, 
gingivitis, and periodontitis, the case presented herein showed 
a far more dramatic condition of poor oral health. The oral 
mucosa had multiple ulcerations, lichenoid lesions, severe 
atrophy, and intense pain, which contributed to the lack of 
compliance to oral health hygiene measures. 
As part of the immunosuppression treatment for his 
multiorgan cGVHD, the patient was initially prescribed 
cyclosporine and prednisone. The worsening of lesions 
led to the use of mycophenolate mofetil (MMF), also with 
poor response. Azathioprine and tacrolimus led to some 
improvements in the symptoms and manifestations (Table 1). 
Some studies have shown that the combination of prolonged 
immunosuppressive treatment for cGVHD increases the risk 
for solid tumors, such as oral SCC. This finding is consistent 
with the case-control study (n = 24,000) by Curtis et al.,9 who 
identified increased risk for oral malignancy and other solid 
tumors in individuals who developed severe cGVHD, and were 
submitted to a long protocol of azathioprine (over 24 months). 
According to these authors, these are the main risk factors for 
the occurrence of skin and oral cavity SCC.3 These findings 
were also described in a large (n = 5,931) solid organ transplant 
study,10 reinforcing that treatment with azathioprine is 
strongly associated with the risk of cutaneous SCC after 
transplantation. The risk of malignancy increases with the 
dose and the duration of treatment. They also found that the 
triple treatment regimen of azathioprine + cyclosporine + 
corticosteroids increases the risk of cutaneous SCC in 5-fold, 
and a high accumulated dose of corticosteroids after prolonged 
treatment (three years) enhances the risk of cutaneous SCC 
in organ transplanted patients. This cumulative association, 
according to their findings, however, was not relevant for 
cyclosporine. 
Immunosuppressive drugs are believed to cause SCC by a 
carcinogenic effect or by increasing the carcinogenic effect of 
other agents combined with its immunosuppressive effect.10 
Azathioprine has been reported as a mutagenic agent, and 
associated to the promotion of secondary malignancies when 
used in cGVHD treatment. On the other hand, cyclosporine 
is not directly associated to an increased risk of SCC, but is 
believed to induce phenotypic changes, and promote tumor 
growth, including invasiveness.8
Due to the severity of his cGVHD and the limited availability 
of other therapeutic tools (extracorporeal photopheresis, 
sirolimus, etc.), our patient was on azathioprine for more than 
34 months, cyclosporine for 26 months, and corticosteroids 
for 56 months, all of which are associated to an increased risk 
for SCC. 
In this case, the presence of multiorgan cGVHD and 
prolonged immunosuppressive therapy are factors that 
could be related to the development of SCC. A periodic and 
thorough oral examination should be recommended for all 
long-term HSCT survivals, with special attention to individuals 
who manifest cGVHD, and those on long-term cumulative 
immunosuppressant therapy. 
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